The procedure for structured capturing and/or saving of manufacturing data for a reproducible production of cosmetic and/or pharmaceutical compositions in a production layout for a reproducible production of these compositions before and/or during the production process, comprises non-extrapolating or extrapolating a meta-manufacturing data from another manufacturing data, and capturing and/or saving the data by a data processing device before and/or during and/or after the production of the compositions by identifying an existing extrapolated/non-extrapolated data. The procedure for structured capturing and/or saving of manufacturing data for a reproducible production of cosmetic and/or pharmaceutical compositions in a production layout for a reproducible production of these compositions before and/or during the production process, comprises non-extrapolating or extrapolating a meta-manufacturing data from another manufacturing data, and capturing and/or saving the data by a data processing device before and/or during and/or after the production of the compositions by identifying an existing extrapolated/non-extrapolated data, which serves as a basis for capturing and/or saving of the data through data sources by identifiable and/or storable link between the extrapolated manufacturing data and the identified and already existing extrapolated/ non-extrapolated manufacturing data, and concatenating the data and the existing extrapolated or non-extrapolated manufacturing data. The production layout has a data processing device, which carries out the procedure and manages the manufacturing data in a data storage space. The saving is carried out in a data storage space. In the absence of an extrapolated/non-extrapolated manufacturing data, a non-extrapolated manufacturing data is acquired and/or saved. The extrapolated/ non-extrapolated manufacturing data has a tag, which indicates whether this manufacturing data is extrapolated or non-extrapolated, and a sub-data, which is identified, captured and/or saved in the storage space by identifiable and/or storable link between the sub-data and another sub-data. The manufacturing data and the sub-data are inputted into the computerized data-processing device and/or displayed on the computerized data-processing device. The sub-data has informations about the composition of the cosmetic/pharmaceutical compositions, total quantity of the composition to be produced, control of the device for the production of the composition, material data and material data with quantity specifications, which furnishes information about the quantity of a substance that is needed for the production of the compositions or quality data, which has quality-related information of the manufacturing data and/or another sub-data. A specification of the tolerance deviation for the quantity of a substance is assigned to a material data with quantity specification and/or a quality parameter data on the quality of the material is assigned to the material that is needed for the production of the compositions. The manufacturing data is extracted partially or completely from information and/or data, which are communicated by a system and/or a device that is included in the production layout, and/or from a data source and/or a lab program included in the production layout for merchandise, and/or from the data and/or information communicated by a point of sale (POS) included in the layout. The device for the production of cosmetic and/or pharmaceutical compositions is used for determining material quantities and transmits a signal that has a material data with quantity specifications, and information about a control parameter of the device to the signal. The procedure has a documentation step of production-relevant steps, which can be concatenated with the manufacturing data and/or the sub-data, and testing and/or identification step of client or patient-specific risk for the manufacturing data. The computerized data processing device has access to the client or patient-related data. A risk profile of a client or patient is determined in the testing and/or identification step of the client or patient-specific risk and the risk profile can be saved and/or concatenated with the data of the patients and/or the manufacturing data. The testing and/or identification step of the client or patient-specific risk has an inclusion of the cave automatic virtual environment (CAVE) module. The procedure has a capturing and/or saving step of taxation of costs and/or cost factors for the production of cosmetic and/or pharmaceutical compositions according to the extrapolated or non-extrapolated manufacturing data. Independent claims are included for: (1) procedure for supervising a reproducible production of cosmetic and/or pharmaceutical compositions in a production layout for the reproducible production of these compositions; and (2) arrangement for the reproducible production of cosmetic and/or pharmaceutical compositions.